scholarly journals Management of Globus Pharyngeus

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
S. Kortequee ◽  
P. D. Karkos ◽  
H. Atkinson ◽  
N. Sethi ◽  
D. C. Sylvester ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Significant Role ◽  
Proton Pump ◽  
Current Evidence ◽  
Extensive Investigation ◽  
Globus Pharyngeus ◽  
Laryngeal Injury ◽  
Benign Nature ◽  
Rigid Oesophagoscopy

Globus pharyngeus is a common ENT condition. This paper reviews the current evidence on globus and gives a rational guide to the management of patients with globus. The aetiology of globus is still unclear though most ENT surgeons believe that reflux whether acidic or not plays a significant role. Though proton pump inhibitors are used extensively in practice, there is little evidence to support their efficacy. Most patients with globus can be discharged after simple office investigations. The role of pepsin-induced laryngeal injury is an exciting concept that needs further study. Given the benign nature of globus pharyngeus, in most cases, reassurance rather than treatment or extensive investigation with rigid oesophagoscopy or contrast swallows is all that is needed. We need more research into the aetiology of globus.

The Role of Proton Pump Inhibitors in Reducing Laryngeal Injury During Prolonged Intubation

2009 ◽  
Vol 119 (S3) ◽  
pp. S264-S264
Author(s):  
Brad W. deSilva ◽  
Michael D. Trudeau ◽  
L. Arick Forrest
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Prolonged Intubation ◽  
Laryngeal Injury

scholarly journals Duodenal Dysbiosis and Relation to the Efficacy of Proton Pump Inhibitors in Functional Dyspepsia

2021 ◽  
Vol 22 (24) ◽  
pp. 13609
Author(s):  
Lucas Wauters ◽  
Raúl Y. Tito ◽  
Matthias Ceulemans ◽  
Maarten Lambaerts ◽  
Alison Accarie ◽  
...  
Keyword(s):  
Functional Dyspepsia ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Potential Role ◽  
Short Term ◽  
Beneficial Effects ◽  
Rrna Sequencing ◽  
Before And After

Proton pump inhibitors (PPI) may improve symptoms in functional dyspepsia (FD) through duodenal eosinophil-reducing effects. However, the contribution of the microbiome to FD symptoms and its interaction with PPI remains elusive. Aseptic duodenal brushings and biopsies were performed before and after PPI intake (4 weeks Pantoprazole 40 mg daily, FD-starters and controls) or withdrawal (2 months, FD-stoppers) for 16S-rRNA sequencing. Between- and within-group changes in genera or diversity and associations with symptoms or duodenal factors were analyzed. In total, 30 controls, 28 FD-starters and 19 FD-stoppers were followed. Mucus-associated Porphyromonas was lower in FD-starters vs. controls and correlated with symptoms in FD and duodenal eosinophils in both groups, while Streptococcus correlated with eosinophils in controls. Although clinical and eosinophil-reducing effects of PPI therapy were unrelated to microbiota changes in FD-starters, increased Streptococcus was associated with duodenal PPI effects in controls and remained higher despite withdrawal of long-term PPI therapy in FD-stoppers. Thus, duodenal microbiome analysis demonstrated differential mucus-associated genera, with a potential role of Porphyromonas in FD pathophysiology. While beneficial effects of short-term PPI therapy were not associated with microbial changes in FD-starters, increased Streptococcus and its association with PPIeffects in controls suggest a role for duodenal dysbiosis after long-term PPI therapy.

scholarly journals Role of altered esophageal intraluminal baseline impedance levels in patients with gatroesophageal reflux disease refractory to proton pump inhibitors

Medicine ◽  
2016 ◽  
Vol 95 (33) ◽  
pp. e4351 ◽  
Author(s):  
Liuqin Jiang ◽  
Bixing Ye ◽  
Lin Lin ◽  
Ying Wang ◽  
Meifeng Wang
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Reflux Disease

Small-bowel bacterial overgrowth

2010 ◽  
pp. 2330-2334
Author(s):  
Richard A. Schatz ◽  
Phillip P. Toskes
Keyword(s):  
Small Bowel ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Case History ◽  
Diagnostic Tool ◽  
Bacterial Overgrowth ◽  
Breath Tests ◽  
Small Bowel Bacterial Overgrowth ◽  
History Of

Case History—A 78 yr old woman presenting with a five-year history of diarrhoea. Updates Pathogenesis—discussion of the possible role of proton pump inhibitors. Diagnosis—comparison of lactulose hydrogen, glucose hydrogen, and 14C D-xylose breath tests; preliminary studies of circulating CdtB antibodies as a diagnostic tool....

scholarly journals Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence

2019 ◽  
Vol 12 ◽  
pp. 175628481983451 ◽  
Author(s):  
Ka Shing Cheung ◽  
Wai K. Leung
Keyword(s):  
Gastric Cancer ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Randomized Clinical Trials ◽  
Bacterial Overgrowth ◽  
Current Evidence ◽  
Neoplastic Progression ◽  
Increased Risk ◽  
H Pylori

Gastric cancer remains one of the leading cancers in the world with a high mortality, particularly in East Asia. Helicobacter pylori infection accounts for the majority of the noncardia gastric cancers by triggering gastric inflammation and subsequent neoplastic progression. Eradication of H. pylori can reduce, but not totally eliminate, subsequent risk of developing gastric cancer. Proton-pump inhibitors (PPIs) are one of the most widely prescribed medications worldwide. With their profound gastric-acid suppression, there are concerns about a possible carcinogenic role in gastric cancer, due to induced hypergastrinemia, gastric atrophy and bacterial overgrowth in the stomach. While randomized clinical trials to establish causality between long-term PPI use and gastric cancer are lacking, current evidence based on observational studies suggests PPIs are associated with an increased gastric cancer risk. However, opinions on causality remain divergent due to unmeasured and possible residual confounding in various studies. Our recent study has showed that even after H. pylori eradication, long-term PPI use is still associated with an increased risk of gastric cancer by more than twofold. Hence, long-term PPIs should be used judiciously after considering individual’s risk–benefit profile, particularly among those with history of H. pylori infection. Further well-designed prospective studies are warranted to confirm the potential role of PPIs in gastric cancer according to baseline gastric histology and its interaction with other chemopreventive agents like aspirin, statins and metformin.

P.04.25 ROLE OF CYP2C19*17 AND CYP2C19*2 IN THE RESPONSE TO PROTON PUMP INHIBITORS TREATMENT IN PATIENTS WITH ESOPHAGITIS

2013 ◽  
Vol 45 ◽  
pp. S118-S119
Author(s):  
M. Franceschi ◽  
D. Seripa ◽  
P. Giulia ◽  
S. Bazzano ◽  
C. Gravina ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump

The Role of Proton Pump Inhibitors on Early Mycophenolic Acid Exposure in Kidney Transplantation: Evidence From the CLEAR Study

2011 ◽  
Vol 33 (1) ◽  
pp. 120-123 ◽  
Author(s):  
Bryce A Kiberd ◽  
Michelle Wrobel ◽  
Raymond Dandavino ◽  
Paul Keown ◽  
Sita Gourishankar
Keyword(s):  
Kidney Transplantation ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Mycophenolic Acid ◽  
Acid Exposure
Sign in / Sign up

Export Citation Format

Share Document